MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/400/0.01/20.12.24 | Real-time Bid/Ask 17:10:11 04/07/2024 BST | ||
| 0.87 EUR / 0.89 EUR | +2.33% |
|
| Current month | -7.53% | ||
| 1 month | -3.37% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 04/07/24 | 0.86 | 0.00% |
| 03/07/24 | 0.86 | -5.49% |
| 02/07/24 | 0.91 | +3.41% |
| 01/07/24 | 0.88 | -5.38% |
| 28/06/24 | 0.93 | +1.09% |
Delayed Quote Börse Stuttgart
Last update July 04, 2024 at 01:50 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME8QNJ |
| ISIN | DE000ME8QNJ2 |
| Date issued | 14/02/2024 |
| Strike | 400 $ |
| Maturity | 20/12/2024 (169 Days) |
| Parity | 100 : 1 |
| Emission price | 0.72 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.02 € |
|---|---|
| Lowest since issue | 0.4 € |
| Spread | 0.02 € |
| Spread % | 2.25% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.3
USD
Average target price
468.3
USD
Spread / Average Target
-0.43%
- Stock Market
- Warrants
- Warrant
